India, China set to lead vaccine distribution in APAC region: Moody’s Analytics

By: |
January 18, 2021 6:09 PM

Moody's Analytics said another pivotal change was Indonesia's formal approval of China's Sinovac vaccine for emergency use, becoming the first country outside China to do so.

The country's success in advancing on this front will eventually soften the severity of the pandemic within the region, it said. The country's success in advancing on this front will eventually soften the severity of the pandemic within the region, it said.

Moody’s Analytics on Monday said India, along with China, would take lead in the COVID-19 vaccine distribution in the Asia-Pacific region.

India launched its vaccination programme on January 16 after the drug regulator?DCGI?earlier this month approved Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute of India, and Bharat Biotech’s indigenously developed Covaxin, for restricted emergency use in the country.

Moody’s Analytics said the Indian government plans to inoculate nearly 300 million high-priority people, including health workers, the elderly, and those with higher comorbidities by August.

“This is an important development. As India is the second most-impacted country in the world, after the US, the need for local immunisation is paramount to contain the significant socioeconomic costs,” Moody’s Analytics added.

The country’s success in advancing on this front will eventually soften the severity of the pandemic within the region, it said.

As the largest producer of vaccines in the world with 60 per cent of the global share, India is well-positioned to contribute to mass vaccine production and distribution needs of other countries in addition to meeting its domestic requirements, said Moody’s Analytics in its report titled ‘Asia’s vaccine update- A step-up in momentum’.

“With exports of the COVID-19 vaccines expected to begin soon, India (along with China) looks set to take the lead in driving the region’s distribution efforts ?in the months ahead,” it added.

Moody’s Analytics said another pivotal change was Indonesia’s formal approval of China’s Sinovac vaccine for emergency use, becoming the first country outside China to do so.

“This is a significant development and could open the door for other Asian economies to follow suit,” it added.

Separately, the Philippines has also approved the Pfizer-BioNTech vaccine for emergency use. The country has one of the highest number of daily COVID-19 infections in Southeast Asia and has been suffering from a protracted first wave of the virus since last spring.

“The Philippines will receive the first batch of vaccines through the COVAX facility, while the government negotiates a bilateral deal with Pfizer.

“COVAX plays a crucial role in providing vaccines for lower-income countries and will smoothen some of the uneven post-pandemic recovery in the region,” it added.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1COVID-19: Next phase of vaccination to begin at 192 health facilities in Delhi on Monday
2Brazil’s capital returns to COVID-19 lockdown
3No words enough to express gratitude towards corona warriors: Health Minister Harsh Vardhan